(Q43167560)

15 November 2017

title

The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy (English)

1 reference

adaptive radiation therapy

15 November 2017

main subject

0 references

1 reference

1 reference

Kevin S Choe

1

1 reference

15 November 2017

David Correa

series ordinal

2

1 reference

15 November 2017

Ashesh B Jani

series ordinal

3

1 reference

15 November 2017

Stanley L Liauw

series ordinal

4

1 reference

15 November 2017

language of work or name

English

0 references

publication date

1 April 2010

1 reference

15 November 2017

number of pages

7

1 reference

inferred from page(s)

published in

Cancer

1 reference

15 November 2017

volume

116

1 reference

15 November 2017

issue

7

1 reference

15 November 2017

page(s)

1820-1826

1 reference

Warfarin inhibits metastasis of Mtln3 rat mammary carcinoma without affecting primary tumour growth

15 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

Deep-vein thrombosis and the incidence of subsequent symptomatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of Cortisone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

Inhibition of metastases by anticoagulants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

Warfarin inhibition of metastasis: the role of anticoagulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

The effect of low molecular weight heparin on survival in patients with advanced malignancy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: Final Report of VA cooperative study # 75

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

Rationale and experimental design for the va cooperative study of anticoagulation (warfarin) in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

Aspirin use and reduced risk of fatal colon cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

Anticoagulants in thrombosis and cancer: the missing link

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

Molecular basis of metastasis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

Efficacy of low-molecular-weight heparin and unfractionated heparin to prevent adhesion of human prostate and bladder carcinoma and melanoma cells to bovine endothelial monolayers. An in vitro study and review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

The hemostatic system as a regulator of angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

Involvement of platelets in tumour angiogenesis?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24890

7 January 2021

Identifiers

DOI

10.1002/CNCR.24890

1 reference

15 November 2017

1 reference